Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.34 |
| ▸ | CCR1 | P32246 | 4/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13167976 | 0.90 | MEN1 (0.41) | SMN1; SMN2KMT2ACCR1 | |
| SCHEMBL15169893 | 0.90 | P2RX3 (0.32) | SMN1; SMN2KMT2ANPY5RP2RX3DRD2 | |
| SCHEMBL13167980 | 0.90 | MEN1 (0.41) | SMN1; SMN2KMT2ACCR1 | |
| SCHEMBL15181600 | 0.90 | NPY5R (0.36) | SMN1; SMN2NPY5RP2RX3DRD2GHSR | |
| SCHEMBL3590166 | 0.88 | MALT1 (0.37) | SMN1; SMN2NPY5RP2RX3DRD2GHSR | |
| SCHEMBL3596229 | 0.85 | LTA4H (0.37) | SMN1; SMN2KMT2ANPY5R | |
| SCHEMBL15169894 | 0.83 | NPY5R (0.34) | NPY5RP2RX3DRD2GHSR | |
| SCHEMBL4441137 | 0.82 | NPY5R (0.34) | NPY5RP2RX3DRD2 | |
| SCHEMBL3598382 | 0.82 | GAA (0.36) | SMN1; SMN2LMNANPY5R | |
| SCHEMBL4441130 | 0.81 | NPY5R (0.36) | SMN1; SMN2POLBKMT2ANPY5RP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | claimed |
| US-8431607-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2013-04-30 | — | — | US | disclosed |
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234365-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | SMN1; SMN2 3746/4885POLB 4041/4885LMNA 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.